Drug Development Technologies
Analysing Protein Stability in the Biopharmaceutical IndustryMalvern Instruments
Monoclonal antibodies (mAb) have a specific binding nature, which allows them to be used to modulate pharmaceutically-relevant molecule activity to control or prevent disease.
A key difference between traditional small molecule pharmaceuticals and biopharmaceuticals is that the latter needs to be processed and delivered in liquid form. Proteins are notoriously unstable in solutions, so approaches need to be developed where these biotherapeutic molecules can be manufactured and stored for long periods in solution without degrading. This is where protein stability has proved invaluable in the development and manufacture of biotherapeutics.
Download to find out more.